Fundraising FoxThe Column Group — 2024 Investments
7 investments dated 2024 · listed companies and verified rows first · show all
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Board seatJeff Goater· per SEC Form D
Co-investorsAtlas VentureForesite CapitalARCH Venture PartnersAlexandriaDecheng Capital
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)AbbVieJJDC+3 more
Tr1X is a biopharmaceutical company developing cell and gene therapies to cure autoimmune and inflammatory diseases with high unmet medical need.
BiotechDeep TechHealthtechMedical Devices
David(Co-Founder)Maria Grazia Roncarolo(Co-Founder, President and Head of R&D)
Co-investorsNeva Sgr.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
RYNE Biotechnology Inc.Site Tx, Inc.Kenai TherapeuticsTr1x
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.